Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Amgen leases 500,000 sq ft in Hyderabad to establish its first global capability centre, enhancing its office space in the ...

For the current quarter, Amgen is expected to post earnings of $5.01 per share, indicating a change of +6.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -3.6% over the last 30 ...